Craig Titmus - Mathys & Squire LLP

Craig holds a bachelor’s degree in molecular biology and biochemistry, as well as a PhD in biotechnology. He works on a wide variety of technical subjects, specialising in the fields of biotechnology, biochemistry and life sciences. Craig is recommended in the latest edition of The Legal 500, in which a source commented that he is “incredibly helpful and collaborative, helping us efficiently and guiding us through many scenarios to identify key risks and rewards with each strategy” (2022). Craig has also been endorsed for being “highly knowledgeable” and recognised for his ability to “consistently meet incredibly tight deadlines” (2021). “Talented biochemist” Craig, who “garners rave reviews for his life sciences adroitness” has been recommended in the IAM Patent 1000 guide for the last five years, where it is noted that “the value Craig adds always exceeds expectations. He is exceptionally supportive, proactive and possesses the rare gift of reducing complexity to simplicity.”

Expertise

Craig’s practice covers diverse biotechnological subject matter, with a particular focus on diagnostics, vaccines, gene editing, therapeutic antibodies, and nucleic acid-based technologies. Craig has significant experience of European and international patent prosecution and opposition proceedings, and he coordinates global IP strategies for a range of clients including startups, SMEs, universities, large corporations, and the UK Government.

Academic

Craig gained a first class bachelor’s degree in molecular biology and biochemistry at the University of Durham, where he ranked top in his year. He went on to the University of Cambridge to undertake a PhD in collaboration with a multinational company, focusing on interfaces between metabolism and the cell cycle. During his time at Cambridge, Craig was awarded various PhD prizes within the Institute of Biotechnology. He also holds a certificate in Intellectual Property from the University of London as well as an Intellectual Property Litigation Certificate.

Memberships & organisations

Craig is a member of the Chartered Institute of Patent Attorneys (CIPA), European Patent Institute (EPI) and has been appointed One Nucleus’ IP Mentor.

Awards

Sectors

Agri-tech

Biotechnology

Cleantech

Life sciences & chemistry

Universities

“Craig Titmus is an exceptionally proactive and diligent practitioner, adept at guiding his clientele through the intricate patent landscape. Craig’s meticulous attention to detail and rapid turnaround times, even on challenging matters, save his clients significant time while consistently securing patent protection across multiple regions.”

IAM Patent 1000 (2025)

“Craig Titmus truly understands start-ups and their unique financial position and is amenable to novel working methods to ensure the steps of patent prosecution are as smooth and cost-effective as possible. He is an invaluable resource to navigate the challenging nature of patent filings, especially when considering different global territories, and offers effective support to reduce the complexity to its most simplified constituent parts.”

IAM Patent 1000 (2024)

“Craig Titmus consistently provides expert strategic advice and guidance on European patent applications. His quality work led to an extraordinarily rapid accelerated EPO intention to grant for a European patent. Craig’s academic background and expertise in biochemistry and biotechnology have been of great value, as have his strategic and technical understanding of patent processes, collaborative approach and management of his patents team supporting this complex work. The value Craig adds always exceeds expectations. He is exceptionally supportive, proactive and possesses the rare gift of reducing complexity to simplicity.”

IAM Patent 1000 (2023)

“Craig Titmus brings dedication, knowledge and humour to our meetings. He clearly has a passion for science and our specific products, delivering assignments with a competitive edge. Craig addresses issues head-on, and delivers quality, in-depth reports even when deadlines are squeezed from 3 months to 3 weeks without notice and without flinching.”

The Legal 500 (2023)

“Craig Titmus has been incredibly helpful and collaborative, helping us efficiently and guiding us through many scenarios to identify key risks and rewards with each strategy. It has certainly helped us define and secure our IP as well as getting it through the many hurdles international process patents require.”

The Legal 500 (2022)

“Working with Craig is great because he is knowledgeable, focused and uses his experience and superb analytical skills in dealing with the various patent offices to get the best outcomes.”

IAM Patent 1000 (2022)

“Craig Titmus pairs the slick management of patent portfolios with an ability to best even the most challenging EPO opposition proceedings. A talented biochemist and an authority on cutting-edge areas like therapeutic antibodies, he is a valuable resource to any life sciences player.”

IAM Patent 1000 (2021)

“Craig Titmus is a “lifesaver” for his slick management of its fabric dye patent portfolio.”

Client reference, IAM Patent 1000 (2020)

“Craig Titmus garners rave reviews for his life sciences adroitness. “He is generous with his time, experience and perspectives, incredibly knowledgeable and always helps us think through the commercial aspects of what we are trying to achieve. He has become a true strategic partner, helping clients far beyond the scope of their existing engagements.”

IAM Patent 1000 (2019)

“Craig Titmus is highly knowledgeable and consistently meets incredibly tight deadlines.”

The Legal 500

Latest articles by Craig Titmus

IAM Patent 1000 2025 recognises thirteen Mathys & Squire attorneys in Gold Tier ranking

Fifteen Mathys & Squire attorneys recognised in IAM Patent 1000 2024

Two new Partners at IP law firm Mathys & Squire